Gastrointestinal Cancer
Neoadjuvant Treatment Crosses Cost-Effective Threshold Vs Upfront Surgery in Pancreatic Cancer
January 27, 2023
Article
Neoadjuvant chemoradiation followed by pancreaticoduodenectomy resulted in 0.14 more quality-of-life years than upfront surgery followed by adjuvant chemotherapy in patients with resectable pancreatic cancer.
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer
January 26, 2023
Article
Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.
Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
January 25, 2023
Article
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
CheckMate 648 Update Showcases Long-Term Survival Benefit With Frontline Nivolumab in ESCC
January 24, 2023
Article
The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
Children Exposed to Maternal Cancer Show Normal Cognitive and Behavioral Outcomes
January 24, 2023
Article
An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.
Retrospective MOUNTAINEER Analysis Sheds Light on Optimal HER2 Testing Practices in mCRC
January 23, 2023
Article
Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.
Zolbetuximab Plus mFOLFOX6 Extends Survival for Patients with CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
January 22, 2023
Article
For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.
Firstline Nivolumab/Chemotherapy Continues To Outperform Chemotherapy Alone for Advanced Gastric/GEJ/Esophageal Cancer At 3-Year Follow-Up
January 21, 2023
Article
In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC
January 20, 2023
Article
Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.
Tucatinib and Trastuzumab Combination Gains FDA Approval for RAS Wild-Type HER2+ mCRC
January 19, 2023
Article
The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.